
Eligible for analysis (n=179)

- · Age between 20 and 90 years
- · Diagnosis with type 2 diabetes currently using metformin
- · Individuals prescribed with dulaglutide at the Seoul National University

 Bundang Hospital Endocrinology and Metabolism clinic
- · HbA1c levels ≤9.0% at baseline before discontinuing dulaglutide



Included in the analysis (n=69)

- · Discontinued dula glutide (n=12)
- · Switched from dulaglutide to DPP4i (n=27)
- · Switched from dulaglutide to SGLT2i (n=26)
- · Switched from dulaglutide to a combination of DPP4i and SGLT2i (n=3)
- · Switched from dulaplutide to thiazolidinedione $(n=1)^a$

Supplemental Fig. S1. Selection criteria and participants allocation in dulaglutide discontinuation study. HbA1c, hemoglobin A1c; GLP1-RA, glucagon-like peptide-1 receptor agonist; DPP4i, dipeptidyl peptidase-4 inhibitor; SGLT2i, sodium glucose cotransporter-2 inhibitor. aNot further analyzed as there was only one participant in the group.